

<b>PHASE 1</b> 2017 – 2018 <i>Initiation: Literature Review</i>	<b>PHASE 2 &amp; 3</b> 2019 – 2021 <i>Understanding Impacts &amp; Patient Prioritization of Impacts</i>	<b>PHASE 4</b> 2021 – 2022 <i>Testing &amp; Finalizing PRIDD</i>	<b>PHASE 5</b> 2022 - 2023 <i>Translate, Cultural Adaptation, Launch PRIDD</i>	<b>PHASE 6</b> 2023+ <i>Data analysis &amp; Application</i>
<b>OBJECTIVES</b>				
<ul style="list-style-type: none"> <li>○ Conduct global scientific scan of patient reported outcomes literature.</li> <li>○ Develop database of patient organizations.</li> </ul>	<ul style="list-style-type: none"> <li>○ Identify issues associated with the patients' diseases.</li> <li>○ Develop new methodology (called GRIP) to collect impact areas.</li> <li>○ Gather primary data from patients via focus groups and interviews.</li> <li>○ Conduct Delphi process to validate and affirm the data.</li> </ul>	<ul style="list-style-type: none"> <li>○ Pilot-test PRIDD with patients and leverage patient insights to make refinements.</li> <li>○ Conduct psychometric testing to make final refinements and quality check PRIDD.</li> </ul>	<ul style="list-style-type: none"> <li>○ Launch PRIDD globally - patient impact measurement tool.</li> <li>○ Report scale development and peer review processes.</li> <li>○ Translate PRIDD into different languages</li> <li>○ Create disease-specific versions of PRIDD</li> </ul>	<ul style="list-style-type: none"> <li>○ Collect global impact data</li> <li>○ Analyze &amp; share GRIDD data.</li> <li>○ Publish articles and reports.</li> <li>○ Educate stakeholders and public.</li> <li>○ Deliver advocacy campaign.</li> <li>○ Offer patient organizations' leader training and support.</li> </ul>
<b>OUTCOMES</b>				
<ul style="list-style-type: none"> <li>○ 12,927 scientific articles reviewed.</li> <li>○ 36 dermatology-specific patient-reported measures identified.</li> <li>○ No measure met Cosmin Category A criteria (i.e. none met gold standard).</li> <li>○ Journal article <a href="#">published in Acta Dermato-Venereologica</a> and results presented at international conferences</li> </ul>	<ul style="list-style-type: none"> <li>○ Patient impact dataset created.</li> <li>○ First draft of new patient impact measurement tool (called PRIDD).</li> <li>○ <a href="#">Poster sessions and paper(s) published on GRIDD research.</a></li> <li>○ Journal article on the impact of dermatological conditions on patients' lives submitted.</li> </ul>	<ul style="list-style-type: none"> <li>○ Pilot and test PRIDD – gold standard patient impact measurement tool.</li> <li>○ Final version of PRIDD patient impact measurement tool developed and launched.</li> <li>○ Poster sessions and paper(s) published on GRIDD research.</li> </ul>	<ul style="list-style-type: none"> <li>○ Scientifically sound cross-cultural and disease-specific versions of PRIDD.</li> <li>○ Poster sessions and paper(s) published on GRIDD research.</li> </ul>	<ul style="list-style-type: none"> <li>○ Produce publications and reports.</li> <li>○ Support advocacy.</li> <li>○ Improve public policy.</li> <li>○ Validate patients' voices.</li> <li>○ Poster sessions and paper(s) published on GRIDD research.</li> </ul>

**BENEFITS of GRIDD**

<b>PATIENT ORGANIZATIONS</b>	<b>DATA &amp; EVIDENCE</b>	<b>ADVOCACY &amp; COMMUNICATIONS</b>	<b>GLOBAL DERMATOLOGY</b>
<ul style="list-style-type: none"> <li>○ Access to data from PRIDD – the world's first dermatology patient impact measurement tool.</li> <li>○ Evidence to support their missions and fundraising.</li> <li>○ Training, resources to support their work and in turn their patients.</li> <li>○ Patient's voice integrated in future decision-making.</li> </ul>	<ul style="list-style-type: none"> <li>○ Gap in patient-driven research now filled that will:               <ul style="list-style-type: none"> <li>• Support publications and reports.</li> <li>• Advance research employing the GRIDD patient impact measurement tool.</li> <li>• Inform better public health policy.</li> <li>• Further center the patient perspective in research (including clinical trials).</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>○ Provide support for GlobalSkin member campaigns to advance their priorities.</li> <li>○ Educate via a global campaign adapted for each country.</li> <li>○ Facilitate informed advocacy at local, regional and country levels to improve diagnosis, care and access to treatments.</li> </ul>	<ul style="list-style-type: none"> <li>○ Advocate via a global campaign to advance dermatology.</li> <li>○ Build a larger global network of dermatology stakeholders.</li> <li>○ Elevate dermatology as a global health care priority (e.g. WHO, UN, Disability-Adjusted Life Years).</li> </ul>